Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature
• Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel i...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gravis, Gwenaëlle [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Using regression analysis to predict the future energy consumption of a supermarket in the UK - Braun, M.R. ELSEVIER, 2014, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:55 ; year:2017 ; pages:211-217 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ctrv.2016.09.008 |
|---|
| Katalog-ID: |
ELV035863498 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035863498 | ||
| 003 | DE-627 | ||
| 005 | 20230624024230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2016.09.008 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017010000007.pica |
| 035 | |a (DE-627)ELV035863498 | ||
| 035 | |a (ELSEVIER)S0305-7372(16)30088-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 620 |q VZ |
| 082 | 0 | 4 | |a 150 |a 300 |q VZ |
| 084 | |a 77.52 |2 bkl | ||
| 100 | 1 | |a Gravis, Gwenaëlle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. | ||
| 650 | 7 | |a Chemotherapy |2 Elsevier | |
| 650 | 7 | |a Androgen deprivation therapy |2 Elsevier | |
| 650 | 7 | |a Docetaxel |2 Elsevier | |
| 650 | 7 | |a Combination therapy |2 Elsevier | |
| 650 | 7 | |a Prostate cancer |2 Elsevier | |
| 700 | 1 | |a Audenet, François |4 oth | |
| 700 | 1 | |a Irani, Jacques |4 oth | |
| 700 | 1 | |a Timsit, Marc-Olivier |4 oth | |
| 700 | 1 | |a Barthelemy, Philippe |4 oth | |
| 700 | 1 | |a Beuzeboc, Philippe |4 oth | |
| 700 | 1 | |a Fléchon, Aude |4 oth | |
| 700 | 1 | |a Linassier, Claude |4 oth | |
| 700 | 1 | |a Oudard, Stéphane |4 oth | |
| 700 | 1 | |a Rebillard, Xavier |4 oth | |
| 700 | 1 | |a Richaud, Pierre |4 oth | |
| 700 | 1 | |a Rouprêt, Morgan |4 oth | |
| 700 | 1 | |a Thiery Vuillemin, Antoine |4 oth | |
| 700 | 1 | |a Vincendeau, Sébastien |4 oth | |
| 700 | 1 | |a Albiges, Laurence |4 oth | |
| 700 | 1 | |a Rozet, François |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Braun, M.R. ELSEVIER |t Using regression analysis to predict the future energy consumption of a supermarket in the UK |d 2014 |g Amsterdam [u.a.] |w (DE-627)ELV01225004X |
| 773 | 1 | 8 | |g volume:55 |g year:2017 |g pages:211-217 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ctrv.2016.09.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 77.52 |j Differentielle Psychologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 55 |j 2017 |h 211-217 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
g g gg |
|---|---|
| matchkey_str |
gravisgwenalleaudenetfranoisiranijacques:2017----:hmteaynomnsniieeattcrsaeacrvdneadnet |
| hierarchy_sort_str |
2017 |
| bklnumber |
77.52 |
| publishDate |
2017 |
| allfields |
10.1016/j.ctrv.2016.09.008 doi GBVA2017010000007.pica (DE-627)ELV035863498 (ELSEVIER)S0305-7372(16)30088-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Gravis, Gwenaëlle verfasserin aut Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Elsevier Audenet, François oth Irani, Jacques oth Timsit, Marc-Olivier oth Barthelemy, Philippe oth Beuzeboc, Philippe oth Fléchon, Aude oth Linassier, Claude oth Oudard, Stéphane oth Rebillard, Xavier oth Richaud, Pierre oth Rouprêt, Morgan oth Thiery Vuillemin, Antoine oth Vincendeau, Sébastien oth Albiges, Laurence oth Rozet, François oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:211-217 extent:7 https://doi.org/10.1016/j.ctrv.2016.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 211-217 7 045F 610 |
| spelling |
10.1016/j.ctrv.2016.09.008 doi GBVA2017010000007.pica (DE-627)ELV035863498 (ELSEVIER)S0305-7372(16)30088-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Gravis, Gwenaëlle verfasserin aut Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Elsevier Audenet, François oth Irani, Jacques oth Timsit, Marc-Olivier oth Barthelemy, Philippe oth Beuzeboc, Philippe oth Fléchon, Aude oth Linassier, Claude oth Oudard, Stéphane oth Rebillard, Xavier oth Richaud, Pierre oth Rouprêt, Morgan oth Thiery Vuillemin, Antoine oth Vincendeau, Sébastien oth Albiges, Laurence oth Rozet, François oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:211-217 extent:7 https://doi.org/10.1016/j.ctrv.2016.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 211-217 7 045F 610 |
| allfields_unstemmed |
10.1016/j.ctrv.2016.09.008 doi GBVA2017010000007.pica (DE-627)ELV035863498 (ELSEVIER)S0305-7372(16)30088-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Gravis, Gwenaëlle verfasserin aut Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Elsevier Audenet, François oth Irani, Jacques oth Timsit, Marc-Olivier oth Barthelemy, Philippe oth Beuzeboc, Philippe oth Fléchon, Aude oth Linassier, Claude oth Oudard, Stéphane oth Rebillard, Xavier oth Richaud, Pierre oth Rouprêt, Morgan oth Thiery Vuillemin, Antoine oth Vincendeau, Sébastien oth Albiges, Laurence oth Rozet, François oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:211-217 extent:7 https://doi.org/10.1016/j.ctrv.2016.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 211-217 7 045F 610 |
| allfieldsGer |
10.1016/j.ctrv.2016.09.008 doi GBVA2017010000007.pica (DE-627)ELV035863498 (ELSEVIER)S0305-7372(16)30088-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Gravis, Gwenaëlle verfasserin aut Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Elsevier Audenet, François oth Irani, Jacques oth Timsit, Marc-Olivier oth Barthelemy, Philippe oth Beuzeboc, Philippe oth Fléchon, Aude oth Linassier, Claude oth Oudard, Stéphane oth Rebillard, Xavier oth Richaud, Pierre oth Rouprêt, Morgan oth Thiery Vuillemin, Antoine oth Vincendeau, Sébastien oth Albiges, Laurence oth Rozet, François oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:211-217 extent:7 https://doi.org/10.1016/j.ctrv.2016.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 211-217 7 045F 610 |
| allfieldsSound |
10.1016/j.ctrv.2016.09.008 doi GBVA2017010000007.pica (DE-627)ELV035863498 (ELSEVIER)S0305-7372(16)30088-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Gravis, Gwenaëlle verfasserin aut Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Elsevier Audenet, François oth Irani, Jacques oth Timsit, Marc-Olivier oth Barthelemy, Philippe oth Beuzeboc, Philippe oth Fléchon, Aude oth Linassier, Claude oth Oudard, Stéphane oth Rebillard, Xavier oth Richaud, Pierre oth Rouprêt, Morgan oth Thiery Vuillemin, Antoine oth Vincendeau, Sébastien oth Albiges, Laurence oth Rozet, François oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:211-217 extent:7 https://doi.org/10.1016/j.ctrv.2016.09.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 211-217 7 045F 610 |
| language |
English |
| source |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:55 year:2017 pages:211-217 extent:7 |
| sourceStr |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:55 year:2017 pages:211-217 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Differentielle Psychologie |
| institution |
findex.gbv.de |
| topic_facet |
Chemotherapy Androgen deprivation therapy Docetaxel Combination therapy Prostate cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| authorswithroles_txt_mv |
Gravis, Gwenaëlle @@aut@@ Audenet, François @@oth@@ Irani, Jacques @@oth@@ Timsit, Marc-Olivier @@oth@@ Barthelemy, Philippe @@oth@@ Beuzeboc, Philippe @@oth@@ Fléchon, Aude @@oth@@ Linassier, Claude @@oth@@ Oudard, Stéphane @@oth@@ Rebillard, Xavier @@oth@@ Richaud, Pierre @@oth@@ Rouprêt, Morgan @@oth@@ Thiery Vuillemin, Antoine @@oth@@ Vincendeau, Sébastien @@oth@@ Albiges, Laurence @@oth@@ Rozet, François @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01225004X |
| dewey-sort |
3610 |
| id |
ELV035863498 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035863498</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624024230.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2016.09.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017010000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035863498</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(16)30088-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gravis, Gwenaëlle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Androgen deprivation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Docetaxel</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Audenet, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Irani, Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timsit, Marc-Olivier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barthelemy, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beuzeboc, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fléchon, Aude</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Linassier, Claude</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oudard, Stéphane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rebillard, Xavier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richaud, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rouprêt, Morgan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thiery Vuillemin, Antoine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vincendeau, Sébastien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albiges, Laurence</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rozet, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:55</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:211-217</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2016.09.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">55</subfield><subfield code="j">2017</subfield><subfield code="h">211-217</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Gravis, Gwenaëlle |
| spellingShingle |
Gravis, Gwenaëlle ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature |
| authorStr |
Gravis, Gwenaëlle |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01225004X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 620 - Engineering & allied operations 150 - Psychology 300 - Social sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer Elsevier |
| topic |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer |
| topic_unstemmed |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer |
| topic_browse |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Chemotherapy Elsevier Androgen deprivation therapy Elsevier Docetaxel Elsevier Combination therapy Elsevier Prostate cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f a fa j i ji m o t mot p b pb p b pb a f af c l cl s o so x r xr p r pr m r mr v a t va vat s v sv l a la f r fr |
| hierarchy_parent_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| hierarchy_parent_id |
ELV01225004X |
| dewey-tens |
610 - Medicine & health 620 - Engineering 150 - Psychology 300 - Social sciences, sociology & anthropology |
| hierarchy_top_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01225004X |
| title |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature |
| ctrlnum |
(DE-627)ELV035863498 (ELSEVIER)S0305-7372(16)30088-3 |
| title_full |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature |
| author_sort |
Gravis, Gwenaëlle |
| journal |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| journalStr |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
211 |
| author_browse |
Gravis, Gwenaëlle |
| container_volume |
55 |
| physical |
7 |
| class |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gravis, Gwenaëlle |
| doi_str_mv |
10.1016/j.ctrv.2016.09.008 |
| dewey-full |
610 620 150 300 |
| title_sort |
chemotherapy in hormone-sensitive metastatic prostate cancer: evidences and uncertainties from the literature |
| title_auth |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature |
| abstract |
• Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. |
| abstractGer |
• Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. |
| abstract_unstemmed |
• Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature |
| url |
https://doi.org/10.1016/j.ctrv.2016.09.008 |
| remote_bool |
true |
| author2 |
Audenet, François Irani, Jacques Timsit, Marc-Olivier Barthelemy, Philippe Beuzeboc, Philippe Fléchon, Aude Linassier, Claude Oudard, Stéphane Rebillard, Xavier Richaud, Pierre Rouprêt, Morgan Thiery Vuillemin, Antoine Vincendeau, Sébastien Albiges, Laurence Rozet, François |
| author2Str |
Audenet, François Irani, Jacques Timsit, Marc-Olivier Barthelemy, Philippe Beuzeboc, Philippe Fléchon, Aude Linassier, Claude Oudard, Stéphane Rebillard, Xavier Richaud, Pierre Rouprêt, Morgan Thiery Vuillemin, Antoine Vincendeau, Sébastien Albiges, Laurence Rozet, François |
| ppnlink |
ELV01225004X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ctrv.2016.09.008 |
| up_date |
2024-07-06T18:41:02.759Z |
| _version_ |
1803856131139829760 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035863498</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624024230.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2016.09.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017010000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035863498</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(16)30088-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gravis, Gwenaëlle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Addition of docetaxel to androgen-deprivation therapy should be the new standard of care for men newly diagnosed with metastatic prostate cancer. • Discriminating factors to identify the best candidates to chemotherapy, like the volume of metastases, need to be validated. • The role of docetaxel in earlier stage of the disease is under investigation.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Androgen deprivation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Docetaxel</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Audenet, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Irani, Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timsit, Marc-Olivier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barthelemy, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beuzeboc, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fléchon, Aude</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Linassier, Claude</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oudard, Stéphane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rebillard, Xavier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richaud, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rouprêt, Morgan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thiery Vuillemin, Antoine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vincendeau, Sébastien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albiges, Laurence</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rozet, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:55</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:211-217</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2016.09.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">55</subfield><subfield code="j">2017</subfield><subfield code="h">211-217</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.398486 |